Tiziana Life Sciences PLC - London-headquartered biotechnology company - Signs agreement for clinical study in Brazil to probe its nasally administered Foralumab medication, alone or with orally administered dexamethasone. Study expected to start in next few weeks. Aim of study is to probe whether Foralumab can suppress a cytokine storm, a potentially life threatening over-reaction of the immune system.
Current stock price: 150.00 pence
Year-to-date change: up sharply from 41.00p
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
